NCT07508930 Russian Extreme Hypertriglyceridemia Registry
| NCT ID | NCT07508930 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Russian Cardiology Research and Production Center |
| Condition | Hypertriglyceridemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2045-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-11-20 with a primary completion date of 2045-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.
Eligibility Criteria
Inclusion Criteria: * Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. * Written informed consent from the patient or legal guardian. * No age restrictions. Exclusion Criteria: * Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. * Lack of informed consent.
Contact & Investigator
Marat Ezhov
PRINCIPAL INVESTIGATOR
MD, PhD
Frequently Asked Questions
Who can join the NCT07508930 clinical trial?
This trial is open to participants of all sexes, studying Hypertriglyceridemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07508930 currently recruiting?
Yes, NCT07508930 is actively recruiting participants. Contact the research team at Marat_Ezhov@mail.ru for enrollment information.
Where is the NCT07508930 trial being conducted?
This trial is being conducted at Astrakhan, Russia, Chelyabinsk, Russia, Kaluga, Russia, Kazan', Russia and 2 additional locations.
Who is sponsoring the NCT07508930 clinical trial?
NCT07508930 is sponsored by Russian Cardiology Research and Production Center. The principal investigator is Marat Ezhov at MD, PhD. The trial plans to enroll 500 participants.